You are here


Ceraxon belongs to the pharmacological group of drugs nootropic and psychostimulating effects on the central nervous system and is a means for improving the metabolism of brain cells. ATX code is N06B X06.

Other trade names: Citicoline, Citimax, Cytokone, Neuroxone, Neocebron, Diphosphocin, Somazine.


N06BX06 Цитиколин

Indications of ceraxon

Tserakson drug used for the treatment of neurological complications and reduce the severity of acute cerebral circulation disorders due to ischemic or hemorrhagic cerebral stroke, traumatic brain injury (involving diffuse axonal brain injury).

Also Tserakson intended for correction of mental, sensory and motor disorders (including dementia, extrapyramidal syndromes, amnesia et al.), Caused by neurosurgery and different latent degenerative encephalopathies.

Release form

Sterile solution for injection (in ampoules), solution for oral administration (in vials).


The neuroprotective effect of the preparation Ceraxon provides the active pharmacological substance citilcoline, which is an analogue of the natural cytidine 5-diphosphocholine natural nucleoside phosphate, a precursor of the molecules lecithin (phosphatidylcholine) and other phospholipids of the cell membranes of neurons and neuroglia.

By integrating into the brain cells and supplying them with choline necessary for the production of the neurotransmitter acetylcholine, Ceraxon promotes the activation of acetylcholine synthesis (which decreases in conditions of brain ischemia), takes part in the production of endogenous phospholipids of cell membranes, improves oxygen supply to the cells, reduces cerebral edema, and prevents peroxidation of lipids in brain tissue cells.

As a result, the stability of membranes of dopaminergic nerve cells increases, which leads to normalization of cerebral metabolism. In addition, the effect of citicoline increases dopamine levels and increases the sensitivity of its receptors, which are responsible for the most important functions of the central nervous system: motivation, attention, memory, cognitive abilities, coordination of fine motor skills,


After parenteral administration of the drug Ceraxon or oral administration, citicoline enters the systemic circulation; bioavailability is almost 99% (regardless of the form of the drug used). The maximum plasma concentration in the plasma is observed 60 minutes after application, and after 24 hours the concentration reaches the second peak.

In the blood serum or in the small intestine, the active substance Ceraxon undergoes hydrolysis with the production of choline and cytidine, which enter the brain and are involved in the production of endogenous cytidine 5-diphosphocholine.

Biotransformation of Ceraxon occurs in the liver and intestines, the resulting free choline is involved in the production of lecithin and membrane lipids.

From the body, citilkoline is eliminated in two stages, mainly through the respiratory tract and, in part, by the kidneys with urine.

Use of ceraxon during pregnancy

Since the use of this drug during pregnancy and lactation has been little studied, it can be used in the treatment of pregnant and lactating women only if the potential benefit to the mother is greater than the potential risks to normal fetal development and the child's health.


Contraindications to the use of the drug Ceraxon are individual hypersensitivity to citilkoline and the presence of vagotonic disorders associated with an increased tone of the parasympathetic nervous system.

Side effects of ceraxon

Application Tserakson drug may cause side effects such as skin allergies, headaches, dizziness, rash, fever, nausea, lowering blood pressure, increased heart rate, shortness of breath, hallucinations appearance.

It does not rule out the possibility of angioneurotic edema and anaphylactic shock.

Dosing and administration

The doses of Ceraxon and the duration of its application depend on the severity of the brain lesions in each specific case.

The drug is administered intramuscularly - 0.5-1 ml twice a day; the maximum allowable daily dose is 20 ml. The course of treatment can last from two weeks to a month three months.

In acute conditions, Ceraxon can be administered intravenously drip - 40-60 cap / min.

The dosage of oral solution is calculated individually for each patient, the maximum duration of oral intake of Ceraxon is three months.


Overdose of this drug is not described.

Interactions with other drugs

It should be borne in mind that the simultaneous application of Ceraxon with the antiparkinsonian drug Levodopa enhances the effect of the latter.

Ceraxon is incompatible with antihypertensive agents, as well as with CNS stimulants, which contain meclofenoxate (Acefen, Centroxin, Cerutil, Analux, Claretil, Meksazine, etc.)

Storage conditions

Ceraxon should be stored at t <+ 25-27 ° C, in a place protected from light. 

Shelf life

Shelf-life of the drug is 36 months.

Found an error? Select it and press Ctrl + Enter.

Share on social networks


To simplify the perception of information, this instruction for use of the drug "Ceraxon" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.